Fundraising FoxSvelte Medical Systems
New Providence, US · Delaware corporation · 1 known investors
Find your way into Svelte Medical Systems
Sign up to see every warm intro you have to Svelte Medical Systems
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Svelte Medical Systems team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
RC
Robert CroceExecutive
JD
Jack DarbyNamed on SEC filing
Board
Investors · 1
New Science VenturesreportedGreenwich · $2M – $8M
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$71.1M disclosed across 4 rounds · 2013–2021
▶$5.4MraisedMay 2021 · 17 investors · BiotechnologyRule 506(b)
▶$5.4MraisedMay 2021 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert CroceExecutive Officer, Director
- Somu SubramaniamDirector
- Richard DakersDirector
- Jack DarbyExecutive Officer, Director
- Robert FlanaganDirector
- Offering amount
- $10.8M
- Amount sold
- $5.4M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedNov 2017 · 10 investors · BiotechnologyRule 506(b)
▶$3MraisedNov 2017 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Phillip D. TorrenceExecutive Officer
- Mark A. KielekExecutive Officer
- Somu SubramaniamDirector
- Robert FlanaganDirector
- Richard DakersDirector
- Jack DarbyExecutive Officer, Director
- Robert CroceExecutive Officer, Director
- Timothy LashDirector
- Offering amount
- $52M
- Amount sold
- $3M
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.3MraisedJul 2017 · 9 investors · BiotechnologyRule 506(b)
▶$12.3MraisedJul 2017 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert CroceExecutive Officer, Director
- Mark A. KielekExecutive Officer
- Phillip D. TorrenceExecutive Officer
- Somu SubramaniamDirector
- Richard DakersDirector
- Jack DarbyExecutive Officer, Director
- Timothy LashDirector
- Robert FlanaganDirector
- Nicholas ValerianiDirector
- Offering amount
- $15M
- Amount sold
- $12.3M
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50.4MraisedJul 2016 · 39 investors · BiotechnologyRule 506(b)
▶$50.4MraisedJul 2016 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark A. KielekExecutive Officer
- Robert FlanaganDirector
- Richard DakersDirector
- Phillip D. TorrenceExecutive Officer
- Somu SubramaniamDirector
- Michael CaponettoDirector
- Jack DarbyExecutive Officer, Director
- Robert CroceExecutive Officer, Director
- Offering amount
- $50.8M
- Amount sold
- $50.4M
- Sales commissions
- $430K
- Proceeds to insiders
- $1.4M
- Placement agents
- Piper Jaffray & Co.
- First sale
- Oct 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Svelte Medical Systems's investors?
- Svelte Medical Systems's investors include New Science Ventures.
- How much funding has Svelte Medical Systems raised?
- Svelte Medical Systems has disclosed $71.1M raised across 4 rounds.
- Where is Svelte Medical Systems headquartered?
- Svelte Medical Systems is headquartered in New Providence, US.